ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
This article was originally published in The Tan Sheet
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry
You may also be interested in...
In a decision that will make executives think twice before taking part in making false claims and other deceptive behavior, an Ohio court sentenced 11 former employees of Berkeley Premium Nutraceuticals to prison for conspiracy, fraud and money laundering convictions related to marketing its Enzyte "natural male enhancement" product
The successful prosecution of Hi-Tech Pharmaceuticals for counterfeiting generic Rx drugs should encourage FDA to pursue criminal charges against other companies selling adulterated products, according to food and drug attorney Marc Ullman
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.